<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258072</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10-054</org_study_id>
    <nct_id>NCT04258072</nct_id>
  </id_info>
  <brief_title>Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.</brief_title>
  <official_title>Phase 1b Study of Vactosertib (TEW-7197) in Combination With Nal-IRI／FL in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine／Nab-Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine recommended phase 2 dose and to evaluate the safety of vactosertib in
      combination with nal-IRI/FL in patients with metastatic pancreatic ductal adenocarcinoma
      (PDAC) who have failed first-line gemcitabine and nab-paclitaxel
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Number of patients : Total 24 patients (6-12 patients in phase 1 part and 12 patients in
           expansion cohort )

        -  Treatment :

             -  Vactosertib* 100-300 mg bid for 5 days

             -  Liposomal Irinotecan (Onivyde) 70mg/m2 on D1

             -  LV 200mg/m2 IV bolus on D1

             -  5-FU 2400mg/m2 CIV over 46 hours on D1

                  -  Vactosertib will be kindly provided by MedPacto.

        -  Disease evaluation: Tumor assessment will be conducted at screening and before Day 1 of
           every third cycle starting with Cycle 4

        -  Period : Approximately 24 months from the date of Institutional Review Board (IRB)
           approval

        -  Primary endpoint : To determine recommended phase 2 dose and to evaluate the safety of
           vactosertib in combination with nal-IRI/FL in patients with metastatic pancreatic ductal
           adenocarcinoma (PDAC) who have failed first-line gemcitabine and nab-paclitaxel

        -  Secondary endpoint :

             -  Progression-Free Survival (PFS) (RECIST 1.1 criteria)

             -  Overall Survival (OS)

             -  Objective Response Rate (ORR) (RECIST 1.1 criteria)

             -  Disease Control Rate (DCR) (RECIST 1.1 criteria)

        -  Exploratory endpoint

             -  Pharmacokinetic assessment: before treatment, post treatment 1.5h, 4.5h, and
                8hPharmacodynamic assessment: to evaluate changes in the amount of p-SMAD in PBMC.

             -  Biomarker analysis in pre-treated and post-treated tumor samples
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Vactosertib* 100-300 mg bid for 5 days
Liposomal Irinotecan (Onivyde) 70mg/m2 on D1
LV 200mg/m2 IV bolus on D1
5-FU 2400mg/m2 CIV over 46 hours on D1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>up to 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>open label,single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vactosertib* 100-300 mg bid for 5 days + Liposomal Irinotecan (Onivyde) 70mg/m2 + LV 200mg/m2 IV bolus + 5-FU 2400mg/m2 CIV over 46 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vactosertib</intervention_name>
    <description>Vactosertib: 50-mg white round film-coated tablets containing excipients (lactose monohydrate Fastflo 316, microcrystalline cellulose Avicel PH 102, crospovidone Kollidon CL-F, povidone Kollidon 30, magnesium stearate, opadry white) and active pharmaceutical ingredient (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), 10% (w/w) of total weight</description>
    <arm_group_label>open label,single arm</arm_group_label>
    <other_name>TEW-7197</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who are males or females ≥ 19 years of age

          2. Subjects who have the following history of first-line gemcitabine-based chemotherapy
             among patients with cytologically or histologically proven metastatic pancreatic
             ductal adenocarcinoma

          3. Subjects who can give written informed consent for participation in this trial after
             receiving explanations of this trial

          4. Subjects who have the following laboratory test values:

               -  bilirubin ≤ 1.5 x ULN (upper limit of normal)

               -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 x ULN

               -  serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 40 mL/min
                  (Cockcroft-Gault)

               -  partial thromboplastin time (aPTT) ≤ 1.5 x ULN

               -  absolute neutrophil count (ANC) ≥ 1,500 cells/µL

               -  platelet count ≥ 100,000/µL

               -  hemoglobin ≥ 9.0 g/dL

          5. Subjects who have at least a 12-week life expectancy at the Investigator's discretion

          6. Subjects who have Eastern Cooperative Oncology Group (ECOG)Performance Status 0-1

        Exclusion Criteria:

          1. Subjects who were treated with surgery, radiotherapy, chemotherapy or investigational
             therapy within 2 weeks (note: placement of biliary stent is allowed)

          2. Subjects who have uncontrolled CNS metastases (patients who require steroids should be
             on a stable or decreasing dose for at least 2 weeks)

          3. Subjects who have any contraindications for 5-FU, leucovorin, or nal-IRI

          4. Subjects who have moderate or severe cardiovascular disease

               -  Subjects who have myocardial infarction, unstable angina pectoris, New York Heart
                  Association (NYHA) Class III/IV congestive heart failure, or uncontrolled
                  hypertension within 6 months before screening

               -  Subjects who have major abnormalities at the Investigator's discretion based on
                  electrocardiogram (ECG)and Doppler ECHO results at screening or within 14 days
                  before screening

               -  Subjects who have increase in brain natriuretic peptide (BNP) or increase in
                  troponin (over 99th percentile upper reference limit) at Screening (based on the
                  normal range of relevant study center)

               -  Subjects who have risk factors for ascending aortic aneurysm such as genetic
                  disorder and trauma and risk factors for aortic stenosis

               -  Subjects who have a history of heart or aorta surgery

          5. Subjects who have clinically significant gastrointestinal bleeding within 4 weeks
             before screening

          6. Subjects who have a known history or suspected hypersensitivity to any excipients of
             the investigational product or combination drug(s)

          7. Subjects who have received prior treatment targeting the signaling pathway of TGF-β

          8. Subjects who have a disease or condition that affects the mechanism of the
             investigational product, or are currently using or planning to use:

               -  Drugs that are exclusively or primarily eliminated by cytochrome P-450 isozyme
                  (CYP) including CYP1A2, CYP2B6, or CYP3A4

               -  Drugs that are exclusively or primarily eliminated by UDP glucuronyltransferase
                  (UGT) 1A1 (UGT1A1)

               -  Drugs that are substrates for the drug transporter multidrug resistance protein 1
                  (MDR1) have a narrow therapeutic window or are strong inhibitors of drug
                  transporter MDR1

               -  Drugs that are strong inhibitors or inducers of CYP2D6 or CYP3A4

          9. Subjects who are unable to swallow tablets

         10. Subjects who have a history of or are suspected of drug abuse

         11. Female subjects of child-bearing potential who have a positive result on a pregnancy
             test at screening or are unable to agree to use an effective barrier method of birth
             control to avoid pregnancy during the study period (e.g., sterilization, intrauterine
             contraceptive device, combination of oral contraception and barrier contraception,
             combination of other hormone delivery systems and barrier contraception, contraceptive
             cream, combination of cream, jelly, or form and diaphragm or condom)

         12. Subjects, in the opinion of the Investigator, who are unsuitable to participate in the
             study

         13. Subjects who were treated with other investigational products within 28 days before
             screening or within a period shorter than 5-timesthe half-life of the investigational
             product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Joon Oh Park</investigator_full_name>
    <investigator_title>M.D., PhD,Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

